New biosensor targets most malignant leukemic stem cells
‘Our biosensor can provide a prototype for precision oncology efforts to target patient-specific leukemic stem cells to fight this deadly disease.’
‘Our biosensor can provide a prototype for precision oncology efforts to target patient-specific leukemic stem cells to fight this deadly disease.’
Hebrew University drug trials show 50% cure rate in lab mice; BioTheryX buys rights to the drug candidate for further development and testing.
Israeli researchers say babies born through fertility treatments are at increased risk of developing many types of pediatric cancers and tumors.
Cellect’s stem-cell selection kit could make bone-marrow transplants as low-risk as getting your appendix out.